{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:11:40Z","timestamp":1790860300254,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":4788,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1993,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prolonged exposure to low concentrations of cytarabine preferentially inhibits in vitro growth of neoplastic myeloid progenitors from patients with chronic myelogenous leukemia (CML) compared to that of normal myeloid progenitors. Continuous infusions of cytarabine in doses of 15\u201330 mg\/m<jats:sup>2<\/jats:sup>\/day were therefore administered for extended periods to patients with CML in stable phase to determine if this treatment could achieve selective cytoreduction of Philadelphia chromosome (Ph)\u2010positive cells. Five patients demonstrating &gt;90% Ph\u2010positive metaphases before treatment received a total of 43 cycles of cytarabine infusional therapy. Cytarabine was administered on an outpatient basis using a portable, battery\u2010operated syringe pump until the total leukocyte count reached 2500\/\u03bcl or the platelet count reached 75,000\/\u03bcl. A new cycle was begun when the total leukocyte count exceeded 4,000\/\u03bcl and the platelet count exceeded 100,000\/\u03bcl. The median duration of cytarabine administration per cycle was 29 days (range 15\u201372 days). Leukocytosis was readily controlled by low\u2010dose cytarabine therapy in all patients. All five patients experienced complete hematologic responses during cytarabine therapy. The fraction of Phpositive metaphases in the marrow of the five patients was reduced to 0, 10%, 43%, 72%, and 84%, respectively, during therapy. The median time to achieve optimal cytogenetic response was 4.8 months (range 2.8\u20138.6 months). One patient demonstrated a complete cytogenetic response after three cycles of cytarabine. Another patient demonstrated persistent cytogenetic improvement during 20 cycles of cytarabine, with a median 38% Ph\u2010positive marrow metaphases (range 10\u201353%) over 32 months. Cytarabine therapy was generally well\u2010tolerated, but was discontinued in one patient because of persistent asymptomatic elevations in hepatic enzymes, which resolved within 2 months after discontinuing therapy. There were no episodes of fever during neutropenia, and platelet transfusions were not required. However, symptomatic anemia requiring transfusion of red cells occurred during most cycles of treatment. In summary, treatment of CML with low\u2010dose cytarabine can induce prolonged cytogenetic improvement in some patients with acceptable toxicity. Further evaluation is needed to ascertain the effects of this treatment on duration of stable phase and overall survival.<\/jats:p>","DOI":"10.1002\/ajh.2830430205","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T13:16:06Z","timestamp":1172063766000},"page":"95-102","source":"Crossref","is-referenced-by-count":27,"title":["Hematologic remission and cytogenetic improvement after treatment of stable\u2010phase chronic myelogenous leukemia with continuous infusion of low\u2010dose cytarabine"],"prefix":"10.1002","volume":"43","author":[{"given":"Michael J.","family":"Robertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramana","family":"Tantravahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Canellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Cannistra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30491-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191506"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132301"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90438-0"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.18.6558"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V73.4.861.861","article-title":"Indications for marrow transplantation in chronic myelogenous leukemia","volume":"73","author":"Thomas ED","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.779"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30493-3"},{"key":"e_1_2_1_13_2","first-page":"1562","article-title":"Regimen\u2010related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman SI","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_14_2","first-page":"62","article-title":"Therapy of chronic myelogenous leukemia: chemotherapy and interferons","volume":"25","author":"Talpaz M","year":"1988","journal-title":"Semin Hematol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-532"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/jnci\/66.6.1053","article-title":"Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myelogenous leukemia to chemotherapeutic agents","volume":"66","author":"Spiro TE","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.7.982"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V65.5.1087.1087"},{"issue":"1","key":"e_1_2_1_21_2","first-page":"208a","article-title":"Clinical pharmacology of low\u2010dose cytosine arabinoside administered by continuous subcutaneous infusion","volume":"66","author":"Sokal JE","year":"1985","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(88)90110-5"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(88)90095-7"},{"key":"e_1_2_1_24_2","first-page":"118","volume-title":"Report of the Standing Committee on Human Cytogenetic Nomenclature","author":"ISCN: An International System for Human Cytogenetic Nomenclature","year":"1985"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112267"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.5.1280.1280"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.1985.3.2.192","article-title":"Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia","volume":"3","author":"Kantarjian HM","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_28_2","first-page":"345","article-title":"Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture","volume":"4","author":"Barnett MJ","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91313-Y"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910615)67:12<2959::AID-CNCR2820671203>3.0.CO;2-T"},{"key":"e_1_2_1_31_2","first-page":"171","article-title":"Combined therapy interferon and chemotherapy in chronic myelogenous leukemia","volume":"31","author":"Guilhot F","year":"1989","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.772"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.2.272"},{"issue":"2","key":"e_1_2_1_34_2","first-page":"62","article-title":"High dose chemotherapy and autologous stem cell reinfusion for patients with chronic myelogenous leukaemia in chronic phase","volume":"4","author":"De Fabritiis P","year":"1989","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"e_1_2_1_35_2","first-page":"51","article-title":"Autografting with blood\u2010derived stem cells for patients with chronic myeloid leukaemia (CML) in chronic phase","volume":"4","author":"Hughes T","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198306233082502"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830430205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830430205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T20:55:38Z","timestamp":1698180938000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830430205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,6]]}},"alternative-id":["10.1002\/ajh.2830430205"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830430205","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,6]]}}}